Activation of the neuregulin/ErbB system during physiological ventricular remodeling in pregnancy

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 300, Issue 3, 2011, Pages

  Lemmens, Katrien ^a   Doggen, Kris ^a   de Keulenaer, Gilles W ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

ErbB receptor; Lapatinib; Neuregulin 1; Pregnancy; Ventricular remodeling

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ISOPROTEIN; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NEU DIFFERENTIATION FACTOR; PROTEIN KINASE B;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DEATH; CONTROLLED STUDY; DRUG EFFECT; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE OVERLOAD; HEART LEFT VENTRICLE PERFORMANCE; HEART MUSCLE FIBROSIS; HEART PAPILLARY MUSCLE; HEART VENTRICLE REMODELING; HEMODYNAMICS; MALE; MATERNAL MORTALITY; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PREGNANCY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; WESTERN BLOTTING;

ANIMALS; FEMALE; GENES, ERBB; MICE; MICE, INBRED C57BL; NEUREGULIN-1; PHOSPHORYLATION; PREGNANCY; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RATS; RATS, SPRAGUE-DAWLEY; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 79955052182     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00385.2010     Document Type: Article

References (29)

1. Bersell K, Arab S, Haring B, Kühn B. Neuregulin1/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injury. Cell 138: 257-270, 2009.
2. Brero A, Ramella R, Fitou A, Dati C, Alloatti G, Gallo MP, Levi R. Neuregulin-1β1 rapidly modulates nitric oxide synthesis and calcium handling in rat cardiomyocytes. Cardiovasc Res 88: 443-452, 2010. 2a. Brutsaert DL, Meulemans AL, Sipido KR, Sys SU. Effects of damaging the endocardial surface on the mechanical performance of isolated cardiac muscle. Circ Res 62: 358-366, 1988.
3. Cote GM, Miller TA, Lebrasseur NK, Kuramochi Y, Sawyer DB. Neuregulin-1alfa and beta isoform expression in cardiac microvascular endothelial cells and function in cardiac myocytes in vitro. Exp Cell Res 311: 135-146, 2005.
4. Crone SA, Zhao Y, Fan L, Gu Y, Minamisawa S, Liu Y, Peterson KL, Chen J, Kahn R, Condorelli G, Ross J, Chien KR, Lee K. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 8: 459-465, 2002.
5. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 57: 450-458, 1986.
6. Doggen K, Ray L, Mathieu M, Mc Entee K, Lemmens K, De Keulenaer GW. Ventricular ErbB2/ErbB4 activation and downstream signaling in pacing-induced heart failure. J Mol Cell Cardiol 46: 33-38, 2009.
7. Dorn GW. The fuzzy logic of physiological cardiac hypertrophy. Hypertension 49: 962-970, 2007.
8. Eghbali M, Deva R, Alioua A, Minosyan TY, Ruan H, Wang Y, Toro L, Stefani E. Molecular and functional signature of heart hypertrophy during pregnancy. Circ Res 96: 1208-1216, 2005.
9. Eghbali M, Wang Y, Toro L, Stefani E. Heart hypertrophy during pregnancy: a better functioning heart? Trends Cardiovasc Med 16: 285-291, 2006.
10. Falls DL. Neuregulins: functions, forms, and signaling strategies. Exp Cell Res 284: 14-30, 2003.
11. Fukazawa R, Miller TA, Kuramochi Y, Frantz S, Kim YD, Marchionni MA, Kelly RA, Sawyer DB. Neuregulin-1 protects ventricular myocytes from anthracycline-induced apoptosis via erbB4-dependent activation of PI3-kinase/Akt. J Mol Cell Cardiol 35: 1473-1479, 2003.
12. Gao R, Zhang J, Cheng L, Wu X, Dong W, Yang X, Li T, Liu X, Xu Y, Li X, Zhou M. A Phase II, randomized, double-blind, multicenter, based on standard therapy, placebo-controlled study of the efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure. J Am Coll Cardiol 55: 1907-1914, 2010.
13. García-Rivello H, Taranda J, Said M, Cabeza-Meckert P, Vila-Petroff M, Scaglione J, Ghio S, Chen J, Lai C, Laguens RP, Lloyd KC, Hertig CM. Dilated cardiomyopathy in Erb-b4-deficient ventricular muscle. Am J Physiol Heart Circ Physiol 289: H1153-H1160, 2005.
14. Gonzalez AMD, Osorio JC, Manlhiot C, Gruber D, Homma S, Mital S. Hypertrophy signaling during peripartum cardiac remodeling. Am J Physiol Heart Circ Physiol 293: H3008-H3013, 2007.
15. Hill JA, Olson EN. Cardiac plasticity. N Engl J Med 358: 1370-1380, 2008.
16. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 357: 39-51, 2007.
17. Kuramochi Y, Guo X, Sawyer DB. Neuregulin activates erbB2-dependent src/FAK signaling and cytoskeletal remodeling in isolated adult rat cardiac myocytes. J Mol Cell Cardiol 41: 228-235, 2006.
18. Lemmens K, Doggen K, De Keulenaer GW. Role of neuregulin-1/ErbB signaling in cardiovascular physiology and disease: implications for therapy of heart failure. Circulation 116: 954-960, 2007.
19. Lemmens K, Fransen P, Sys SU, Brutsaert DL, De Keulenaer GW. Neuregulin-1 induces a negative inotropic effect in cardiac muscle: role of nitric oxide synthase. Circulation 109: 324-326, 2004.
20. Lemmens K, Segers VFM, Demolder M, De Keulenaer GW. Role of neuregulin-1/ErbB2 signaling in endothelium-cardiomyocyte cross-talk. J Biol Chem 281: 19469-19477, 2006.
21. Liu X, Gu X, Li Z, Li X, Li H, Chang J, Chen P, Jin J, Xi B, Chen D, Lai D, Graham RM, Zhou M. Neuregulin-1/erbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy. J Am Coll Cardiol 48: 1438-1447, 2006.
22. McMullen JR, Jennings GL. Differences between pathological and physiological cardiac hypertrophy: novel therapeutic strategies to treat heart failure. Clin Exp Pharmacol Physiol 34: 255-262, 2007.
23. Pentassuglia L, Graf M, Lane H, Kuramochi Y, Cote G, Timolati F, Sawyer DB, Zuppinger C, Suter TM. Inhibition of ErbB2 by receptor tyrosine kinase inhibitors causes myofibrillar structural damage without cell death in adult rat cardiomyocytes. Exp Cell Res 315: 1302-1312, 2009.
24. Pentassuglia L, Sawyer DB. The role of Neuregulin-1beta/ErbB signaling in the heart. Exp Cell Res 315: 627-637, 2009.
25. Perez EA, Koehler M, Byrne J, Preston AJ, Rappold E, Ewer MS. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc 83: 679-686, 2008.
26. Rohrbach S, Niemann B, Silber R, Holtz J. Neuregulin receptors erbB2 and erbB4 in failing human myocardium: depressed expression and attenuated activation. Basic Res Cardiol 100: 240-249, 2005.
27. Sawyer DB, Zuppinger C, Miller TA, Eppenberger HM, Suter TM. Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity. Circulation 105: 1551-1554. 2002.
28. Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, Murphy M, Stewart SJ, Keefe D. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20: 1215-1221, 2002.
29. Teichholz LE, Kreulen T, Herman MV, Gorlin R. Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence of absence of asynergy. Am J Cardiol 37: 7-11, 1976.